Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNO as Adjunctive Treatment for Cerebral Malaria in Children
NCT01388842Phase 2Completed
- Sponsor
- Illumina
- Start
- Sep 2011
- Primary completion
- Feb 2014
- Modality
- Transdermal Patches, Inhalation Devices, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Nitric oxide-releasing solution in cerebral malaria (CM), sponsored by Illumina. Primary endpoint: Angiopoietin 1 at 48 hours. Started Sep 2011; status: completed.
02
Drugs
Nitric oxide-releasing solution
03
Conditions
cerebral malaria (CM)
Beyond the preview
Go deeper on NCT01388842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01388842.